The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

Stephens & Co. analyst Sudan Loganathan downgraded Blueprint Medicines Corporation (NASDAQ:BPMC) to Equal Weight from ...

Citizens JMP analyst Reni Benjamin downgraded Blueprint Medicines Corporation (NASDAQ:BPMC) to Market Perform from Outperform ...

This week on "The Readout LOUD" podcast: an AI experiment at the FDA and how Novo Nordisk is trailing in the obesity drug ...

Breakingviews provides financial professionals with unique agenda-setting insight on the major financial news stories as they ...

Breakingviews provides financial professionals with unique agenda-setting insight on the major financial news stories as they ...

Nintendo's Switch 2 launches to overwhelming demand and limited supply. Analysts predict strong early sales and long-term ...